Key facts
- 1928 Diagnostics’s last known valuation is $31.6M (Dec 2019).
- It has raised $12.3M; the latest was Later Stage VC ($310K) in Jul 2025.
- Notable investors include Chalmers Ventures, Chalmers Innovation, Horizon 2020, Sciety.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for 1928 Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for 1928 Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 1928 Diagnostics
Developer of a bioinformatics platform designed to support microbiologists in taking advantage of their sequencing data. The company's platform offers a cloud service for the analysis of genomic data for outbreak tracing and identification of bacteria, and viruses, enabling doctors to effectively track and minimize the spread of bugs globally.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2013
- Employees
- 12
- Website
- 1928diagnostics.com/
- Ownership
- Privately Held (backing)
1928 Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 1928 Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 1928 Diagnostics in its N-PORT filings yet. We sweep new filings monthly.